- Category: Pipeline
Pipeline
ViaLase's IDE trial treats first patient with novel femtosecond laser procedure
Pivotal study is comparing ViaLuxe Laser System with FLigHT as an incision-free canal procedure against SLT for POAG treatment.
Pipeline
FDA clears Zhongmou Therapeutics' IND for RP optogenetic gene therapy
Clearance of ZM-02 marks the first optogenetic gene therapy originating from China to receive U.S. IND authorization.
Pipeline
Belite Bio reports phase 3 topline data on oral tinlarebant for Stargardt disease
DRAGON study is evaluating the once-daily tablet for reducing lesion growth among adolescent patients over a 24-month period.
Pipeline
Precise Bio performs first transplant with 3D-printed cornea implant
Procedure deemed successful in treating first fully blind patient using corneal bio-implant made from corneal endothelial cells.
Pipeline
First autofocus glasses offer lightweight vision correction
New prototype design for prescription-based smart eyewear could be an alternative to traditional progressive lenses.
Pipeline
Ocuvex resubmits FDA CRL for brimonidine tartrate 0.35% NDA
Shared by partner SPARC, update follows 2+ years after the 2022 submission of investigational OAG and OHT eye drop was rejected in July 2023.
Pipeline
Coave Therapeutics debuts lead SCS gene therapy for retinal vascular diseases
In-office, suprachoroidal delivery of CoTx-101 offers potential for durable and long-lasting vision gains in treating wet AMD and DME.
Pipeline
PolyActiva and RareSight to advance long-acting therapies for pediatric IRDs
Collaboration leverages PolyActiva’s PREZIA drug delivery platform to develop NCE-enabling pharmacologic drugs for early-onset vision loss.
Pipeline
SpyGlass Pharma reports long-term data on bimatoprost IOL system
Positive 36-month findings from an FIH trial and 3-month results from a phase 1/2 study support delivery of sustained IOP reduction and drop-free outcomes for OAG, OHT.
Pipeline
Lilly gains exclusive global rights to MeiraGTx's ophthalmic genetic therapies
Strategic partnership extends to MeiraGTx’s investigational genetic medicine for LCA4-AIPLI-associated congenital blindness among pediatric patients.
Pipeline
Outlook Therapeutics resubmits wet AMD BLA for bevacizumab
Company’s third submission of ONS-5010 (bevacizumab-vikg) reportedly addresses prior issues raised in the FDA’s company response letter.
Pipeline
Sydnexis reports phase 3 topline data on SYD-101 eye drop for pediatric myopia
The STAR study met both primary and secondary endpoints for low-dose atropine formulation—just days after the FDA’s NDA rejection.
Pipeline
Viridian submits BLA for veligrotug to treat TED
Company is requesting Priority Review of veli, an IGF-1R monoclonal antibody intravenously-administered to treat chronic TED.
Pipeline
Nanoscope reports 3-year vision improvements for RP optogenetic therapy
Long-term extension from phase 2b/3 RESTORE trial notes potential of MCO-010 as a one-time, gene-agnostic optogenetic therapy.
Pipeline
FDA rejects Sydnexis’ NDA for low-dose atropine drop
SYD-101 still has the potential to become the first pharmaceutical option for progressive myopia for patients aged 3 to 14.
Pipeline
Complement Therapeutics' GA gene therapy IND receives FDA clearance
Clearance gives green light to begin Q1 2026 patient enrollment for the Opti-GAIN study evaluating CTx001 as a one-time, durable treatment.
Pipeline
Dompé receives FDA priority voucher for NAION intranasal therapy
New expedited pilot program cuts the standard application review time for investigational candidates from 10 to 12 months to just 1 to 2 months.
Pipeline
Nanoscope's optogenetic therapy demonstrates visual improvements for Stargardt
Findings from phase 2 STARLIGHT trial support the safety and efficacy of MCO-010 in Stargardt disease.
Pipeline
FDA grants IDE approval for Avisi's glaucoma treatment device
IDE approval enables initiation of the open-label SAPPHIRE to evaluate the VisiPlate, an aqueous shunt designed to lower IOP among OAG patients.
Pipeline